One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics
T-cell engaging biologics is a class of novel and promising immune-oncology compounds that leverage the immune system to eradicate cancer. Here, we compared and contrasted a bispecific diabody-Fc format, which displays a relatively short antigen-binding arm distance, with our bispecific IgG platform...
Main Authors: | Wei Chen, Fan Yang, Carole Wang, Jatin Narula, Edward Pascua, Irene Ni, Sheng Ding, Xiaodi Deng, Matthew Ling-Hon Chu, Amber Pham, Xiaoyue Jiang, Kevin C. Lindquist, Patrick J. Doonan, Tom Van Blarcom, Yik Andy Yeung, Javier Chaparro-Riggers |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2020.1871171 |
Similar Items
-
The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use
by: Rita Tavarozzi, et al.
Published: (2022-02-01) -
T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions
by: David A. Russler-Germain, et al.
Published: (2023-07-01) -
Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
by: Roa Alsajjan, et al.
Published: (2023-09-01) -
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
by: Jing Wei, et al.
Published: (2022-10-01) -
Bispecific antibodies in multiple myeloma treatment: A journey in progress
by: Shih-Feng Cho, et al.
Published: (2022-10-01)